Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial

Table 5 Analysis of the association of leptin and HMW-APN with radiographic spinal progression after 2 years

	OR unadjusted	95% CI	OR adjusted^a	95% CI
Outcome: no mSASSS progression after 2 years (logistic regression)
Leptin, ng/mL	1.06	1.003 to 1.12	1.16	1.03 to 1.29
Leptin/BMI	9.20	1.44 to 58.7	28.7	2.24 to 367.7
HMW-APN, μg/mL	1.12	0.98 to 1.27	1.17	0.99 to 1.38
HMW-APN/BMI	9.68	0.48 to 196.2	10.7	0.35 to 320.6
HMW-APN/APN	10.81	1.25 to 93.5	22.2	1.57 to 313.1
Outcome: no syndesmophyte formation/progression after 2 years (logistic regression)
Leptin, ng/mL	1.07	1.002 to 1.14	1.29	1.11 to 1.50
Leptin/BMI	36.5	3.29 to 404.5	131.9	4.78 to 3638
HMW-APN, μg/mL	1.18	1.01 to 1.39	1.18	0.98 to 1.42
HMW-APN/BMI	34.3	0.89 to 1319	23.8	0.41 to 1382
HMW-APN/APN	10.9	1.11 to 106.3	10.8	0.74 to 156.1

^aAdjusted for the presence of syndesmophytes at baseline, C-reactive protein at baseline, sex, non-steroidal anti-inflammatory drugs intake score over 2 years, and smoking status at baseline. Models with leptin, HMW-APN and HMW-APN/APN ratio were additionally adjusted for body mass index (BMI). APN adiponectin, CI confidence interval, HMW-APN high molecular weight adiponectin, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, OR odds ratio

ISSN: 1478-6362